AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2021
Jan 4, 2021
31542_dirs_2021-01-04_429fbd99-322b-4c87-9268-fc8d011e519c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2020-12-30
Reporting Person: Elsbernd Brian (Chief Compliance/Legal Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-12-30 | Options to purchase common stock | $3.42 | A | 200000 | Acquired | 2027-12-30 | Common Stock (200000) | Direct |
Footnotes
F1: Options vest in equal tranches, 1/3rd on December 30, 2021, 1/3rd on December 30, 2022 and 1/3rd on December 30, 2023.
More from CATALYST PHARMACEUTICALS, INC.
M&A Activity
2026
Jun 8
Report Publication Announcement
2026
May 11
M&A Activity
2026
May 7
Major Shareholding Notification
2026
Mar 26
Earnings Release
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Investor Presentation
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6